2022
Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer
Press BH, Jones T, Olawoyin O, Lokeshwar SD, Rahman SN, Khajir G, Lin DW, Cooperberg MR, Loeb S, Darst BF, Zheng Y, Chen RC, Witte JS, Seibert TM, Catalona WJ, Leapman MS, Sprenkle PC. Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer. European Urology Open Science 2022, 37: 113-119. PMID: 35243396, PMCID: PMC8883188, DOI: 10.1016/j.euros.2022.01.008.Peer-Reviewed Original ResearchDecipher scoreMultivariable logistic regressionGleason grade groupActive surveillanceProstate cancerBiopsy GleasonBiopsy upgradingGG2 diseaseGenomic classifierFavorable intermediate-risk prostate cancerBiopsy Gleason grade groupIntermediate-risk prostate cancerLogistic regressionDecipher genomic classifierHigher Decipher scoresRetrospective cohort studyBaseline clinical variablesHigh-grade diseaseBiopsy reclassificationDecipher testDecipher testingGleason upgradeCohort studyMedian ageClinical variables
2021
NCCN Risk Reclassification in Black Men with Low and Intermediate Risk Prostate Cancer After Genomic Testing
Seiden B, Weng S, Sun N, Gordon D, Harris W, Barnett J, Myrie A, Jones T, Pak S, Fudl A, Shields J, McNeil B, Weiss J, Smith M, Esdaille A, Winer A. NCCN Risk Reclassification in Black Men with Low and Intermediate Risk Prostate Cancer After Genomic Testing. Urology 2021, 163: 81-89. PMID: 34688772, DOI: 10.1016/j.urology.2021.08.055.Peer-Reviewed Original ResearchConceptsNCCN riskIntermediate riskGenomic testingLower riskPre-biopsy prostate specific antigenNational Comprehensive Cancer Network guidelinesIntermediate-risk prostate cancerFavorable intermediate riskNCCN risk classificationPre-biopsy PSARisk classificationRisk prostate cancerUnfavorable intermediate riskProstate-specific antigenInitial risk classificationMedian ageBlack patientsNetwork guidelinesActive surveillanceProstate cancerHigher oddsSpecific antigenNonparametric statistical testingPatientsRisk